Successful use of argatroban as an anticoagulant in burn-related severe acquired antithrombin III deficiency after heparin failure

Thrombosis and Haemostasis

Volumn 86, Issue 6, 2001, Pages 1596-1597

  Gorman, R ^a   Gordan, L ^a   Zumberg, M ^a   Kitchens, C ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN III; ARGATROBAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HEPARIN; NITRATE; PROTEIN C; PROTEIN S; THROMBIN INHIBITOR; WARFARIN;

ADULT; ANTICOAGULATION; ANTITHROMBIN III DEFICIENCY; BURN; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HUMAN; LETTER; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL;

EID: 0035652424     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616778     Document Type: Letter

References (11)

1. Development of Argatroban, a direct thrombin inhibitor, and its clinical application
2. The effect of burn wound size on hemostasis: A correlation of the hemostatic changes to the clinical state
3. Degree of hypercoagulability and hyper-fibrinolysis is related to organ failure and prognosis after burn trauma
4. Antithrombin (H) concentrate infusions are safe and effective in patients with thermal injuries
5. Comparative study on heparin and a synthetic thrombin inhibitor No. 805 (MD-805) in experimental antithrombin III-deficient animals
6. Clinical application of the synthetic thrombin inhibitor, Argatroban (MD-805)
7. Clinical application of Argatroban as an alternative anticoagulant for extracorporeal circulation
8. Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for the treatment of disseminated intravascular coagulation
9. The pharmacokinetics and pharmacodynamics of Argatroban: Effects of age, gender, and hepatic or renal dysfunction
10. Effects of a new synthetic anticoagulant (MD805) on platelets
11. Direct thrombin inhibitors in cardiovascular medicine